The popular painkiller Vioxx was pulled off the market on September 30, 2004 by Merck & Company after new data from a three-year study confirmed that it increases a patients' risk of cardiovascular events, such as heart attack and stroke. U.S. Food and Drug Administration approved Vioxx in 1999 for the reduction of pain and inflammation caused by arthritis, as well as for acute pain in adults and for the treatment of menstrual pain. Vioxx has been marketed in more than 80 countries. In some countries, the painkiller is marketed under the name Ceoxx. Merck estimates 105 million U.S. prescriptions were written for Vioxx from May 1999 through August 2004. The company believes that nearly 20 million patients are taking Vioxx in the United States. Worldwide sales of Vioxx in 2003 were $2.5 billion. Find a Vioxx Lawyer Vioxx News Merck - Up to its Ears in Lawsuits and Probes from SEC and DOJ Vioxx Lawsuit Filed Against Merck and Walgreens in Florida Vioxx Class Action Lawsuit Filed Against Merck in Florida Vioxx Class Action Lawsuit Filed Against Merck in Kentucky Canadians File Vioxx Class Action Lawsuit Texas Woman Files Vioxx Lawsuit After Undergoing Heart Surgery Vioxx Class Action Lawsuit Filed Against Merck in Illinois Chicago Law Firm Files Vioxx Class Action Lawsuit against Merck Vioxx Pulled from Market by Merck Oklahoma City Law Firm Files Vioxx Lawsuit Against Merck Study: Higher Doses of Vioxx can Raise Risk of Heart Attacks Australia Issues Warning Over Common Prescription Drugs Vioxx Resources Merck Merck Clarifies Number of Patients and Prescriptions for VIOXX Merck Announces Voluntary Worldwide Withdrawal of VIOXX Merck Vioxx U.S. Food and Drug Administration U.S. Food and Drug Administration Vioxx Center FDA Public Health Advisory on Vioxx FDA Vioxx Questions and Answers U.S. Food and Drug Administration